Rhythm Pharmaceuticals, Inc.
RYTM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3,415 | $2,651 | $1,518 | $495 |
| - Cash | $89 | $60 | $128 | $59 |
| + Debt | $257 | $1 | $2 | $3 |
| Enterprise Value | $3,582 | $2,592 | $1,392 | $438 |
| Revenue | $130 | $77 | $24 | $3 |
| % Growth | 68.1% | 227.6% | 649.5% | – |
| Gross Profit | $117 | $68 | $22 | $3 |
| % Margin | 89.7% | 88% | 91% | 81% |
| EBITDA | -$238 | -$168 | -$174 | -$68 |
| % Margin | -183% | -217.6% | -737.1% | -2,170.4% |
| Net Income | -$261 | -$185 | -$181 | -$70 |
| % Margin | -200.3% | -238.5% | -766.2% | -2,207.1% |
| EPS Diluted | -4.34 | -3.2 | -3.51 | -1.37 |
| % Growth | -35.6% | 8.8% | -156.2% | – |
| Operating Cash Flow | -$114 | -$136 | -$173 | -$146 |
| Capital Expenditures | $0 | -$0 | -$4 | -$5 |
| Free Cash Flow | -$114 | -$136 | -$178 | -$151 |